Aristeia Capital L.L.C. Acquires Shares of 4,797 Prestige Consumer Healthcare Inc. $PBH

Key Points

• Aristeia Capital L.L.C. acquired a new position in Prestige Consumer Healthcare Inc. by purchasing 4,797 shares valued at approximately $412,000 during the 1st quarter.
• Prestige Consumer Healthcare's stock was recently downgraded by Zacks from a "hold" to a "strong sell" rating, with a consensus rating of "Hold" and a target price of $93.33.
• The company reported a net margin of 19.02% and a revenue of $249.53 million for the last quarter, falling short of expectations and down 6.6% compared to the same period last year.

Aristeia Capital L.L.C. acquired a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 4,797 shares of the company's stock, valued at approximately $412,000.

A number of other hedge funds have also modified their holdings of the company. Opal Wealth Advisors LLC acquired a new position in shares of Prestige Consumer Healthcare during the 1st quarter worth approximately $38,000. McIlrath & Eck LLC boosted its holdings in shares of Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after buying an additional 154 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of Prestige Consumer Healthcare in the 1st quarter valued at approximately $112,000. GAMMA Investing LLC boosted its holdings in shares of Prestige Consumer Healthcare by 35.9% in the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock valued at $162,000 after buying an additional 496 shares during the last quarter. Finally, KBC Group NV boosted its holdings in shares of Prestige Consumer Healthcare by 7.4% in the 1st quarter. KBC Group NV now owns 2,199 shares of the company's stock valued at $189,000 after buying an additional 151 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on PBH shares. Canaccord Genuity Group cut their price objective on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a report on Friday, August 8th. Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Zacks Research cut Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $93.33.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH traded down $1.71 during mid-day trading on Friday, hitting $63.31. 560,980 shares of the stock were exchanged, compared to its average volume of 569,221. The stock has a market capitalization of $3.12 billion, a price-to-earnings ratio of 14.86, a price-to-earnings-growth ratio of 2.06 and a beta of 0.46. The firm's 50-day simple moving average is $70.53 and its 200 day simple moving average is $79.23. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. Prestige Consumer Healthcare Inc. has a fifty-two week low of $62.95 and a fifty-two week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business's revenue for the quarter was down 6.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.